Methadone’s Hidden Cardiac Risk: Major Review Links Therapy to Dangerous Heart Rhythm Changes

Methadone has helped millions of people escape the grip of opioid addiction, but a new systematic review is sounding an alarm that clinicians and patients cannot afford to ignore. The analysis, published in BMC Pharmacology and Toxicology, brings together evidence from 25 studies and concludes that methadone maintenance therapy is consistently associated with prolongation of the QTc interval, an electrical measurement of the heart’s recharging phase that, when stretched too far, can set the stage for potentially fatal ventricular arrhythmias. The finding does not mean methadone should be abandoned; it means the drug must be prescribed and monitored with a level of cardiac vigilance that many treatment programs have yet to adopt.

The research team, led by investigators at Mazandaran University of Medical Sciences in Iran along with collaborators at several other Iranian institutions, conducted the review in accordance with PRISMA guidelines, the international standard for reporting systematic reviews. They searched Embase, PubMed, and Scopus for studies published up to 2025, with two reviewers independently selecting studies, extracting data, and assessing report quality using the STROBE checklist, a tool designed to evaluate the rigor of observational research. Because the included studies differed substantially in design, populations, and outcome measures, the authors chose a narrative synthesis rather than a statistical meta-analysis, a decision that reflects the messy reality of real-world evidence but also limits the precision of any single pooled estimate.

To understand why this matters, it helps to know what the QTc interval actually represents. Every heartbeat is triggered by an electrical impulse that sweeps through the ventricles, the heart’s main pumping chambers, causing them to contract and push blood to the body. After contraction, the cardiac cells must electrically reset before the next beat can occur, and the duration of that reset is measured on the electrocardiogram as the QT interval. Because the raw QT shortens as heart rate increases, clinicians apply a correction formula, producing the QTc value. When QTc is prolonged, the heart’s electrical recovery is delayed, creating a window in which stray electrical signals can trigger a distinctive and dangerous rhythm called torsades de pointes, a form of polymorphic ventricular tachycardia that can degenerate into sudden cardiac arrest.

Methadone interferes with this reset process by blocking hERG potassium channels, the molecular pores in cardiac cell membranes that allow potassium ions to flow outward during the repolarization phase. This is the same mechanism implicated in a long list of drugs that have been withdrawn or black-boxed over the past decades, from certain antihistamines to some antipsychotics. Methadone’s blockade is dose-dependent, meaning higher concentrations of the drug in the blood translate into greater channel inhibition and longer QTc intervals. The synthetic opioid’s long and variable half-life, along with wide differences between individuals in how their livers metabolize it through the CYP enzyme system, means that blood levels can vary dramatically between patients taking what appears to be the same dose.

The review’s synthesis of the 25 included studies points to several consistent patterns. First, the association between methadone and QTc prolongation appears dose-related, with patients on higher doses showing greater electrical changes. Second, the effect is more pronounced in female patients, a sex difference that echoes broader cardiac electrophysiology, since women inherently have longer baseline QTc intervals and appear more susceptible to drug-induced repolarization delays, particularly during hormonal fluctuations. Third, and perhaps most actionable for practicing clinicians, concomitant medications amplify the risk, with benzodiazepines standing out as a particularly concerning co-prescription. Many patients in methadone maintenance programs also receive benzodiazepines for anxiety, insomnia, or co-occurring psychiatric conditions, often without either prescriber fully appreciating the cumulative cardiac burden.

Notably, the review reports that several studies documented QTc prolongation even at relatively low methadone doses. This finding challenges a common clinical assumption that only patients on high-dose methadone, typically defined as exceeding 100 milligrams per day in many guidelines, require cardiac scrutiny. If electrical changes can emerge at modest doses, then dose thresholds alone are an unreliable safeguard, and individual vulnerability factors, including genetic variations in potassium channel genes, electrolyte disturbances such as low potassium or magnesium, structural heart disease, and liver impairment, become critical pieces of the risk puzzle. Patients with any of these features may be pushed across the arrhythmia threshold by exposures that would be tolerated by healthier hearts.

The clinical implications are substantial because methadone occupies a unique and indispensable position in addiction medicine. As a full opioid agonist with a long duration of action, it stabilizes patients, suppresses withdrawal and cravings, and is associated with reduced illicit opioid use, reduced overdose mortality, and improved retention in treatment. Buprenorphine, a partial agonist, offers an alternative with a comparatively more favorable cardiac profile, but it does not suit every patient, and switching therapies carries its own risks of relapse and dropout. The review’s authors therefore do not call for restricting access to methadone; instead, they underscore the importance of careful cardiac monitoring and individualized risk assessment, positioning the findings as a call for smarter prescribing rather than frightened abstinence from an effective therapy.

What would smarter prescribing look like in practice? The evidence assembled in this review supports a layered approach. Before initiating methadone, clinicians can obtain a baseline electrocardiogram and review the patient’s medication list for other QT-prolonging agents, including certain antidepressants, antipsychotics, macrolide antibiotics, and antiarrhythmic drugs. Serum potassium and magnesium levels can be checked and corrected where needed. Follow-up electrocardiograms become especially important after dose increases, after adding interacting medications, and in patients with liver disease, since impaired metabolism can raise methadone blood concentrations unpredictably. Patients should be educated about warning symptoms, including fainting episodes, palpitations, and seizures, which may represent arrhythmic events rather than benign phenomena. When benzodiazepine co-prescription is unavoidable, the combination warrants heightened surveillance and honest conversations about the added risk.

The review also highlights structural gaps in how methadone programs operate. Many opioid treatment clinics, particularly in low-resource settings, lack routine access to electrocardiography, and screening practices vary widely between and within countries. The authors of the review received no external funding and declared no competing interests, and their synthesis draws exclusively on previously published literature, which means the quality of the underlying studies shapes the strength of the conclusions. Observational studies are vulnerable to confounding, since patients on high-dose methadone often differ from those on low doses in ways that independently affect cardiac health, including duration of opioid use, co-occurring diseases, and lifestyle factors. The narrative format of the synthesis, while appropriate given the heterogeneity, means the review cannot quantify a single pooled risk estimate, and the authors are careful not to overstate what the data support.

Nevertheless, the consistency of the signal across 25 independent studies is difficult to dismiss, and the biological mechanism is well understood. For the millions of people currently in methadone maintenance therapy worldwide, the message is not panic but partnership: patients deserve to know that their medication carries a measurable cardiac risk that is manageable with proper monitoring, and clinicians deserve clear, evidence-based protocols for identifying who is most vulnerable. As opioid use disorder continues to drive devastating mortality globally, the challenge for the field is to preserve the life-saving benefits of methadone while closing the surveillance gaps that allow a treatable electrical abnormality to progress unnoticed toward a preventable tragedy. This review provides the evidence base for that conversation, and it arrives at a moment when the addiction treatment community is actively rethinking how safety monitoring should be built into every prescription.

Subject of Research: QTc prolongation and cardiac arrhythmia risk associated with methadone maintenance therapy

Article Title: Risk factors and clinical implications of QTc prolongation in methadone maintenance therapy: a systematic review

Article References: Alaedini Shoormasti, K., Behroozi, Z., Souresrafil, A., Salimi, M., Sefidgarnia Amiri, M., Zarghami, M., & Tashakori-Miyanroudi, M. (2026). Risk factors and clinical implications of QTc prolongation in methadone maintenance therapy: a systematic review. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01251-8

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01251-8

Keywords: methadone, QTc prolongation, opioid substitution therapy, ventricular arrhythmia, torsades de pointes, drug safety, cardiac monitoring, benzodiazepines, systematic review, hERG potassium channels, pharmacology, addiction medicine